[Seroprevalence of hepatitis A in hemophiliacs].
OBJECTIVE
To study the seroprevalence of hepatitis A virus (HAV) infection in haemophiliacs treated with factor VIII/IX concentrates.


METHODS
Anti-HAV IgG antibodies were tested in 133 haemophiliacs previously treated (20 of them only infused with virus-inactivated factor concentrates), 11 previously untreated haemophiliacs and 60 healthy individuals (> 25 yr. old).


RESULTS
The overall anti-HAV prevalence was 43%. Anti-HAV was found in 2 (10%) of the patients treated only with virus-inactivated concentrates and in 55 (49%) of those who had received non-inactivated concentrates. The seroprevalence in the untreated haemophiliacs was 27% and 90% in the healthy control group. The anti-HAV seroprevalence showed a significant (p < 0.001) dependence on patient age, it being higher in patients aged > 25 (77%) than in those aged 10-25 (31%) and < 10 (4%). The seroprevalence of anti-HAV was lower in the treated haemophiliacs aged 25 or more than in the healthy individuals, although the difference did not reach statistical significance (p = 0.06).


CONCLUSIONS
These results show that the seroprevalence of HAV infection in haemophiliacs is similar to that in the general population, and that there is not a significant excess of HAV infections amongst haemophiliacs with high exposure to coagulation factor concentrates.
Molina
R
R
Unidad de Coagulopatías Congénitas, Hospital La Fe, Valencia.
Lorenzo
J I
JI
Gómez
M D
MD
Sarrión
A
A
Haya
S
S
Querol
F
F
Aznar
J A
JA
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D015897:Comorbidity; D006467:Hemophilia A / Q000453:epidemiology*; D006506:Hepatitis A / Q000453:epidemiology* / Q000209:etiology; D035922:Hepatitis A Antibodies; D006508:Hepatitis Antibodies / Q000097:blood; D006801:Humans; D015995:Prevalence; D065227:Transfusion Reaction
D035922:Hepatitis A Antibodies; D006508:Hepatitis Antibodies